143 related articles for article (PubMed ID: 35779236)
1. Timing of Live Attenuated Vaccination in Infants Exposed to Infliximab or Adalimumab in Utero: A Prospective Cohort Study in 107 Children.
Liu Z; Julsgaard M; Zhu X; Martin J; Barclay ML; Cranswick N; Gibson PR; Gearry RB; van der Giessen J; Connor SJ; Rosella O; Grosen A; Toong C; Flanagan E; Wieringa JW; Janneke van der Woude C; Bell SJ;
J Crohns Colitis; 2022 Dec; 16(12):1835-1844. PubMed ID: 35779236
[TBL] [Abstract][Full Text] [Related]
2. Concentrations of Adalimumab and Infliximab in Mothers and Newborns, and Effects on Infection.
Julsgaard M; Christensen LA; Gibson PR; Gearry RB; Fallingborg J; Hvas CL; Bibby BM; Uldbjerg N; Connell WR; Rosella O; Grosen A; Brown SJ; Kjeldsen J; Wildt S; Svenningsen L; Sparrow MP; Walsh A; Connor SJ; Radford-Smith G; Lawrance IC; Andrews JM; Ellard K; Bell SJ
Gastroenterology; 2016 Jul; 151(1):110-9. PubMed ID: 27063728
[TBL] [Abstract][Full Text] [Related]
3. Validation of the Pharmacokinetic Model for Anti-TNFα Clearance in Infants Exposed to Anti-TNFα During Pregnancy.
Wieringa JW; Kruizinga MD; Driessen GJA; van der Woude CJ; Julsgaard M
J Crohns Colitis; 2024 Apr; 18(4):506-515. PubMed ID: 37823516
[TBL] [Abstract][Full Text] [Related]
4. Vaccines in Children Exposed to Biological Agents In Utero and/or During Breastfeeding: Are They Effective and Safe?
Gisbert JP; Chaparro M
J Crohns Colitis; 2023 Jun; 17(6):995-1009. PubMed ID: 36652274
[TBL] [Abstract][Full Text] [Related]
5. Physiologically-Based Pharmacokinetic Modeling of Anti-Tumor Necrosis Factor Agents for Inflammatory Bowel Disease Patients to Predict the Withdrawal Time in Pregnancy and Vaccine Time in Infants.
Chen J; Lin R; Guo G; Wu W; Ke M; Ke C; Huang P; Lin C
Clin Pharmacol Ther; 2023 Dec; 114(6):1254-1263. PubMed ID: 37620249
[TBL] [Abstract][Full Text] [Related]
6. Hepatitis B Vaccination Effective in Children Exposed to Anti-Tumour Necrosis Factor Alpha in Utero.
de Lima A; Kanis SL; Escher JC; van der Woude CJ
J Crohns Colitis; 2018 Jul; 12(8):948-953. PubMed ID: 29726943
[TBL] [Abstract][Full Text] [Related]
7. Health outcomes of 1000 children born to mothers with inflammatory bowel disease in their first 5 years of life.
Kanis SL; Modderman S; Escher JC; Erler N; Beukers R; de Boer N; Bodelier A; Depla ACTM; Dijkstra G; van Dijk ARM; Gilissen L; Hoentjen F; Jansen JM; Kuyvenhoven J; Mahmmod N; Mallant-Hent RC; van der Meulen-de Jong AE; Noruzi A; Oldenburg B; Oostenbrug LE; Ter Borg PCJ; Pierik M; Romberg-Camps M; Thijs W; West R; de Lima A; van der Woude CJ;
Gut; 2021 Jul; 70(7):1266-1274. PubMed ID: 33046558
[TBL] [Abstract][Full Text] [Related]
8. Safety of Anti-TNF-Alpha Therapy During Pregnancy on Long-term Outcome of Exposed Children: A Controlled, Multicenter Observation.
Duricova D; Dvorakova E; Hradsky O; Mitrova K; Durilova M; Kozeluhova J; Kohout P; Zarubova K; Bronsky J; Hradska N; Bronska E; Adamcova M; Machkova N; Hruba V; Bortlik M; Lukas M; Malickova K; Lukas M
Inflamm Bowel Dis; 2019 Mar; 25(4):789-796. PubMed ID: 30239799
[TBL] [Abstract][Full Text] [Related]
9. The Effect of Maternal Peripartum Anti-TNFα Use on Infant Immune Response.
Sheibani S; Cohen R; Kane S; Dubinsky M; Church JA; Mahadevan U
Dig Dis Sci; 2016 Jun; 61(6):1622-7. PubMed ID: 26725061
[TBL] [Abstract][Full Text] [Related]
10. A systematic review of live vaccine outcomes in infants exposed to biologic disease modifying anti-rheumatic drugs in utero.
Goulden B; Chua N; Parker E; Giles I
Rheumatology (Oxford); 2022 Oct; 61(10):3902-3906. PubMed ID: 35258557
[TBL] [Abstract][Full Text] [Related]
11. Infliximab, adalimumab and vedolizumab concentrations across pregnancy and vedolizumab concentrations in infants following intrauterine exposure.
Flanagan E; Gibson PR; Wright EK; Moore GT; Sparrow MP; Connell W; Kamm MA; Begun J; Christensen B; De Cruz P; Shelton E; Dowling D; Andrews JM; Brown SJ; Niewiadomski O; Ward MG; Rosella O; Rosella G; Kiburg KV; Ross AL; Bell SJ;
Aliment Pharmacol Ther; 2020 Nov; 52(10):1551-1562. PubMed ID: 32981127
[TBL] [Abstract][Full Text] [Related]
12. Management of inflammatory bowel disease and serum level of infliximab in newborn exposed to anti-TNF therapy during pregnancy: Case report and literature review.
de Aragão MC; Beraldo RF; Marcondes MB; de Barros JR; Herrerias GSP; Saad-Hossne R; Baima JP; Sassaki LY
Medicine (Baltimore); 2021 Dec; 100(51):e28274. PubMed ID: 34941109
[TBL] [Abstract][Full Text] [Related]
13. Anti-TNF Levels in Cord Blood at Birth are Associated with Anti-TNF Type.
Kanis SL; de Lima-Karagiannis A; van der Ent C; Rizopoulos D; van der Woude CJ
J Crohns Colitis; 2018 Jul; 12(8):939-947. PubMed ID: 29771301
[TBL] [Abstract][Full Text] [Related]
14. Implications for sequencing of biologic therapy and choice of second anti-TNF in patients with inflammatory bowel disease: results from the IMmunogenicity to Second Anti-TNF therapy (IMSAT) therapeutic drug monitoring study.
Chanchlani N; Lin S; Auth MK; Lee CL; Robbins H; Looi S; Murugesan SV; Riley T; Preston C; Stephenson S; Cardozo W; Sonwalkar SA; Allah-Ditta M; Mansfield L; Durai D; Baker M; London I; London E; Gupta S; Di Mambro A; Murphy A; Gaynor E; Jones KDJ; Claridge A; Sebastian S; Ramachandran S; Selinger CP; Borg-Bartolo SP; Knight P; Sprakes MB; Burton J; Kane P; Lupton S; Fletcher A; Gaya DR; Colbert R; Seenan JP; MacDonald J; Lynch L; McLachlan I; Shields S; Hansen R; Gervais L; Jere M; Akhtar M; Black K; Henderson P; Russell RK; Lees CW; Derikx LAAP; Lockett M; Betteridge F; De Silva A; Hussenbux A; Beckly J; Bendall O; Hart JW; Thomas A; Hamilton B; Gordon C; Chee D; McDonald TJ; Nice R; Parkinson M; Gardner-Thorpe H; Butterworth JR; Javed A; Al-Shakhshir S; Yadagiri R; Maher S; Pollok RCG; Ng T; Appiahene P; Donovan F; Lok J; Chandy R; Jagdish R; Baig D; Mahmood Z; Marsh L; Moss A; Abdulgader A; Kitchin A; Walker GJ; George B; Lim YH; Gulliver J; Bloom S; Theaker H; Carlson S; Cummings JRF; Livingstone R; Beale A; Carter JO; Bell A; Coulter A; Snook J; Stone H; Kennedy NA; Goodhand JR; Ahmad T;
Aliment Pharmacol Ther; 2022 Oct; 56(8):1250-1263. PubMed ID: 36039036
[TBL] [Abstract][Full Text] [Related]
15. Immunological effects and safety of live rotavirus vaccination after antenatal exposure to immunomodulatory biologic agents: a prospective cohort study from the Canadian Immunization Research Network.
Fitzpatrick T; Alsager K; Sadarangani M; Pham-Huy A; Murguía-Favela L; Morris SK; Seow CH; Piché-Renaud PP; Jadavji T; Vanderkooi OG; Top KA; Constantinescu C;
Lancet Child Adolesc Health; 2023 Sep; 7(9):648-656. PubMed ID: 37390832
[TBL] [Abstract][Full Text] [Related]
16. Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease.
Mahadevan U; Wolf DC; Dubinsky M; Cortot A; Lee SD; Siegel CA; Ullman T; Glover S; Valentine JF; Rubin DT; Miller J; Abreu MT
Clin Gastroenterol Hepatol; 2013 Mar; 11(3):286-92; quiz e24. PubMed ID: 23200982
[TBL] [Abstract][Full Text] [Related]
17. Use of Biologic Therapy by Pregnant Women With Inflammatory Bowel Disease Does Not Affect Infant Response to Vaccines.
Beaulieu DB; Ananthakrishnan AN; Martin C; Cohen RD; Kane SV; Mahadevan U
Clin Gastroenterol Hepatol; 2018 Jan; 16(1):99-105. PubMed ID: 28870657
[TBL] [Abstract][Full Text] [Related]
18. Long-Term Safety of In Utero Exposure to Anti-TNFα Drugs for the Treatment of Inflammatory Bowel Disease: Results from the Multicenter European TEDDY Study.
Chaparro M; Verreth A; Lobaton T; Gravito-Soares E; Julsgaard M; Savarino E; Magro F; Biron AI; Lopez-Serrano P; Casanova MJ; Gompertz M; Vitor S; Arroyo M; Pugliese D; Zabana Y; Vicente R; Aguas M; Shitrit BA; Gutierrez A; Doherty GA; Fernandez-Salazar L; Cadilla MJ; Huguet JM; OʼToole A; Stasi E; Marcos MN; Villoria A; Karmiris K; Rahier JF; Rodriguez C; Palomares DM; Fiorino G; Benitez JM; Principi M; Naftali T; Taxonera C; Mantzaris G; Sebkova L; Iade B; Lissner D; Bradley FI; Roman LA; Marin-Jimenez I; Merino O; Sierra M; Van Domselaar M; Caprioli F; Guerra I; Peixe P; Piqueras M; Rodriguez-Lago I; Ber Y; van Hoeve K; Torres P; Gravito-Soares M; Rudbeck-Resdal D; Bartolo O; Peixoto A; Martin G; Armuzzi A; Garre A; Donday MG; de Carpi MFJ; Gisbert JP
Am J Gastroenterol; 2018 Mar; 113(3):396-403. PubMed ID: 29460920
[TBL] [Abstract][Full Text] [Related]
19. Effects of discontinuing anti-tumor necrosis factor therapy during pregnancy on the course of inflammatory bowel disease and neonatal exposure.
Zelinkova Z; van der Ent C; Bruin KF; van Baalen O; Vermeulen HG; Smalbraak HJ; Ouwendijk RJ; Hoek AC; van der Werf SD; Kuipers EJ; van der Woude CJ;
Clin Gastroenterol Hepatol; 2013 Mar; 11(3):318-21. PubMed ID: 23103819
[TBL] [Abstract][Full Text] [Related]
20. The effects of pregnancy on the pharmacokinetics of infliximab and adalimumab in inflammatory bowel disease.
Seow CH; Leung Y; Vande Casteele N; Ehteshami Afshar E; Tanyingoh D; Bindra G; Stewart MJ; Beck PL; Kaplan GG; Ghosh S; Panaccione R
Aliment Pharmacol Ther; 2017 May; 45(10):1329-1338. PubMed ID: 28318043
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
